
    
      is a multicenter, randomized, double-blind, placebo-controlled phase II study. The trial
      includes a Run-in Period (if stable conventional treatment needed), a 4-week Screening
      Period, a 12-week Treatment Period, and a 3-week Safety Follow-up Period to Day 105.

      90 patients will be centrally, dynamically, randomly assigned to 3 groups (1:1:1) to receive
      600mg TJ301 Q2W, 300mg TJ301 Q2W or placebo Q2W.
    
  